Cross-topic event
China approves three "global first" drugs on the same day: bispecific ADC, solid-tumor CAR-T, and rabies bispecific antibody
Jun 22, 2026
Sciencedesk view
China approves three "global first" drugs on the same day: bispecific ADC, solid-tumor CAR-T, and rabies bispecific antibody
Per Sina Finance on June 22, 2026, China's NMPA approved three domestically developed drugs with global-first or leading labels: (1) Betta Pharma's EGFR×HER3 bi…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
China's first solid-tumor CAR-T approved; gastric cancer survival nearly doubles
Per Sina Finance on June 22, CARsgen's satri-cel (brand: 恺力美) became the world's first approved solid-tumor CAR-T therapy in China. A multicenter RCT showed med…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
First-in-class EGFR×HER3 bispecific ADC approved for recurrent NPC
Per Sina Finance on June 22, Sichuan Biokin's izalontamab brengitecan (伦康依隆妥单抗) was approved for adults with recurrent/metastatic nasopharyngeal carcinoma after…
READ THE DAY'S DIGEST →